Today's trading session saw pharmaceutical stocks bucking the broader market trend and posting strong gains.

Stocks including JOINN Laboratories and others surged by the daily limit.

The catalyst for the movement was an earnings forecast from JOINN Laboratories, which projected its net profit for the first half of 2026 to reach between 6 and 9 billion yuan, representing a staggering year-on-year increase of approximately 884.9% to 1377.4%.

The company attributed this massive projected growth primarily to rising prices for laboratory monkeys.

As a leading domestic player in non-clinical CRO services, JOINN Laboratories holds significant resources in these research primates.

Stimulated by this forecast, market capital began flowing into related sectors connected to laboratory animals and the broader supply chain.

Some market participants have even jokingly begun referring to this thematic investment trend using a term that translates to "monkey module."

Industry sources indicate that prices for laboratory monkeys have risen sharply in recent years, driven by growing demand and constrained supply.

Market information suggests prices for certain animals have approached 200,000 yuan each, with the supply-demand imbalance not yet fully resolved.

As the focus on these primates intensified, a wave of creative and humorous stock correlations emerged during the trading day.

For instance, shares of a fruit and vegetable distributor spiked, with online commentators humorously noting that bananas, a product it sells, are a staple food for monkeys, making it an "upstream" supplier.

Similarly, shares of a tourism company associated with a famous mountain saw a sharp intraday rise, with investors quipping that the location is well-known for its large population of wild monkeys.